Literature DB >> 28460888

Healthcare provider compliance with the 2013 ACC/AHA Adult Cholesterol Guideline recommendation for high-intensity dose statins for patients with coronary artery disease.

Susan D Housholder-Hughes1, Melanie M Martin2, Marilyn R McFarland3, Constance J Creech3, Michael J Shea4.   

Abstract

BACKGROUND: Atherosclerotic cardiovascular disease is the foremost cause of death for U.S. adults. The 2013 ACC/AHA Adult Cholesterol Guidelines recommend high-intensity dose statins for individuals with coronary artery disease (CAD).
OBJECTIVE: To determine healthcare provider compliance with the Cholesterol Guideline recommendation specific to high-intensity dose statins for patients with CAD.
METHODS: A retrospective chart review was conducted to determine compliance rate. A questionnaire was developed to evaluate healthcare provider beliefs, attitudes, and self-confidence toward this recommendation.
RESULTS: Of the 473 patients with CAD, 67% were prescribed a high-intensity dose statin. Patients with non-ST segment myocardial infarction and ST segment myocardial infarction were more likely to be prescribed a high-intensity dose statin versus a moderate or low-intensity dose. Healthcare providers strongly agreed with this guideline recommendation.
CONCLUSION: There exists a dichotomy between intention to prescribe and actual prescribing behaviors of high-intensity dose statin for patients with CAD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerotic cardiovascular disease; Cholesterol guidelines; Healthcare provider compliance; Quality improvement; Statins

Mesh:

Substances:

Year:  2017        PMID: 28460888     DOI: 10.1016/j.hrtlng.2017.03.005

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  1 in total

1.  Physicians Voluntarily Using an EHR-Based CDS Tool Improved Patients' Guideline-Related Statin Prescription Rates: A Retrospective Cohort Study.

Authors:  Timothy S Chang; Ashwin Buchipudi; Gregg C Fonarow; Michael A Pfeffer; Jennifer S Singer; Eric M Cheng
Journal:  Appl Clin Inform       Date:  2019-06-19       Impact factor: 2.342

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.